Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes.

Journal

PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404

Informations de publication

Date de publication:
Mar 2020
Historique:
pubmed: 22 1 2020
medline: 22 1 2020
entrez: 22 1 2020
Statut: ppublish

Résumé

Unfortunately, the article's Supplementary File Link is not working and the ESM material.

Identifiants

DOI: 10.1007/s40273-020-00885-8 PMID: 31960352
pubmed: 31960352
doi: 10.1007/s40273-020-00885-8
pii: 10.1007/s40273-020-00885-8
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

315

Commentaires et corrections

Type : ErratumFor

Auteurs

Laura Panattoni (L)

School of Population Health, University of Auckland, Auckland, New Zealand. laura.e.panattoni@gmail.com.
Department of Health Policy Research, Palo Alto Medical Foundation Research Institute, 2350 W. El Camino Real, Mountain View, California, CA, 94040, USA. laura.e.panattoni@gmail.com.

Paul M Brown (PM)

School of Population Health, University of Auckland, Auckland, New Zealand.
School of Social Sciences, Humanities and Arts, University of California, Merced, CA, USA.

Braden Te Ao (BT)

School of Population Health, University of Auckland, Auckland, New Zealand.

Mark Webster (M)

School of Medicine, University of Auckland, Auckland, New Zealand.
Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.

Patrick Gladding (P)

School of Medicine, University of Auckland, Auckland, New Zealand.
Cleveland Clinic Foundation, Cleveland, OH, USA.
Theranostics Laboratory, Cleveland, OH, USA.

Classifications MeSH